NASDAQ:CAMP CAMP4 Therapeutics Q2 2026 Earnings Results & Report $3.70 -0.14 (-3.65%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$3.74 +0.04 (+1.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CAMP4 Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.58 versus the -$0.24 consensus estimate, while revenue was $1.78 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeAfter Market ClosesConference Call7:00 AM ET CAMP4 Therapeutics EPS ResultsActual EPS-$0.58Consensus EPS -$0.24Beat/MissMissed by -$0.34One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCAMP4 Therapeutics Revenue ResultsActual Revenue$1.78 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CAMP4 Therapeutics Q2 2026 Earnings FAQ Did CAMP4 Therapeutics beat earnings estimates for Q2 2026? CAMP4 Therapeutics (NASDAQ:CAMP) reported earnings of -$0.58 per share for Q2 2026, missing the consensus estimate of -$0.24. The report was announced on Thursday, August 13, 2026. What was CAMP4 Therapeutics' revenue for Q2 2026? CAMP4 Therapeutics reported revenue of $1.78 million for Q2 2026. CAMP4 Therapeutics Earnings HeadlinesOppenheimer Initiates Coverage on CAMP4 Therapeutics With Outperform Rating, $15 Price TargetOctober 5, 2026 | marketscreener.comMOppenheimer Begins Coverage on CAMP4 Therapeutics (NASDAQ:CAMP)October 5, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 9 at 1:00 AM | InvestorPlace (Ad)Chardan Capital Issues Pessimistic Forecast for CAMP4 Therapeutics (NASDAQ:CAMP) Stock PriceOctober 1, 2026 | americanbankingnews.comCAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated "Moderate Buy" by Wall Street AnalystsSeptember 30, 2026 | americanbankingnews.comChardan Trims Price Target on CAMP4 Therapeutics to $6 From $6.50, Keeps Buy RatingSeptember 29, 2026 | marketscreener.comMSee More CAMP4 Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CAMP4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CAMP4 Therapeutics and other key companies, straight to your email. Email Address About CAMP4 TherapeuticsCAMP4 Therapeutics (NASDAQ:CAMP) is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them. CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins. Its research programs are aimed at diseases in which restoring or increasing the activity of an underexpressed gene could address the underlying cause of illness. The company’s lead program, CAMP4-001, is being developed for phenylketonuria, an inherited metabolic disorder associated with inadequate activity of the phenylalanine hydroxylase gene. CAMP4 Therapeutics is headquartered in Cambridge, Massachusetts, and is led by President and Chief Executive Officer Josh Mandel-Brehm.View CAMP4 Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
